Michael P. Gosland

1.2k total citations
21 papers, 1.1k citations indexed

About

Michael P. Gosland is a scholar working on Oncology, Molecular Biology and Epidemiology. According to data from OpenAlex, Michael P. Gosland has authored 21 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 12 papers in Molecular Biology and 5 papers in Epidemiology. Recurrent topics in Michael P. Gosland's work include Drug Transport and Resistance Mechanisms (11 papers), Cancer therapeutics and mechanisms (8 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Michael P. Gosland is often cited by papers focused on Drug Transport and Resistance Mechanisms (11 papers), Cancer therapeutics and mechanisms (8 papers) and Immunodeficiency and Autoimmune Disorders (3 papers). Michael P. Gosland collaborates with scholars based in United States. Michael P. Gosland's co-authors include Bert L. Lum, Branimir I. Šikić, B L Lum, Sonja Kaubisch, Joanne Halsey, N A Brophy, George A. Fisher, Mary Vore, Tim Hoffman and James F. Baker and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and Journal of Pharmacology and Experimental Therapeutics.

In The Last Decade

Michael P. Gosland

21 papers receiving 1.0k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Michael P. Gosland United States 16 763 451 294 117 113 21 1.1k
C.M. Kuiper Netherlands 15 1.1k 1.4× 665 1.5× 278 0.9× 90 0.8× 214 1.9× 21 1.4k
C. H. M. Versantvoort Netherlands 11 848 1.1× 411 0.9× 307 1.0× 71 0.6× 175 1.5× 14 992
C.K. van Kalken Netherlands 13 808 1.1× 475 1.1× 241 0.8× 77 0.7× 238 2.1× 17 1.1k
Kieran L. O’Loughlin United States 20 928 1.2× 764 1.7× 230 0.8× 90 0.8× 114 1.0× 33 1.7k
Elizabeth Hopper-Borge United States 18 954 1.3× 638 1.4× 243 0.8× 97 0.8× 168 1.5× 20 1.5k
Junko Mitsuhashi Japan 19 722 0.9× 537 1.2× 118 0.4× 59 0.5× 103 0.9× 29 1.1k
Ken Shiozawa Japan 16 861 1.1× 687 1.5× 196 0.7× 90 0.8× 174 1.5× 24 1.3k
Irina Shchaveleva United States 9 851 1.1× 386 0.9× 293 1.0× 75 0.6× 173 1.5× 10 1.1k
G L Scheffer Netherlands 13 1.3k 1.7× 780 1.7× 308 1.0× 101 0.9× 274 2.4× 14 1.7k
D D Ross United States 13 1.1k 1.5× 698 1.5× 357 1.2× 55 0.5× 154 1.4× 15 1.4k

Countries citing papers authored by Michael P. Gosland

Since Specialization
Citations

This map shows the geographic impact of Michael P. Gosland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Michael P. Gosland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Michael P. Gosland more than expected).

Fields of papers citing papers by Michael P. Gosland

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Michael P. Gosland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Michael P. Gosland. The network helps show where Michael P. Gosland may publish in the future.

Co-authorship network of co-authors of Michael P. Gosland

This figure shows the co-authorship network connecting the top 25 collaborators of Michael P. Gosland. A scholar is included among the top collaborators of Michael P. Gosland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Michael P. Gosland. Michael P. Gosland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Gosland, Michael P., et al.. (1999). Activation of Human Peripheral Blood T Cells Does Not Lead to Increased P-Glycoprotein Expression. Journal of Clinical Immunology. 19(4). 239–246. 5 indexed citations
2.
3.
Gosland, Michael P., et al.. (1996). Insights into Mechanisms of Cisplatin Resistance and Potential for Its Clinical Reversal. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 16(1). 16–39. 59 indexed citations
4.
Gosland, Michael P., et al.. (1996). Reversal of doxorubicin, etoposide, vinblastine, and taxol resistance in multidrug resistant human sarcoma cells by a polymer of spermine. Cancer Chemotherapy and Pharmacology. 37(6). 593–600. 18 indexed citations
5.
6.
Burgio, David E., Michael P. Gosland, & Patrick J. McNamara. (1996). Modulation effects of cyclosporine on etoposide pharmacokinetics and CNS distribution in the rat utilizing microdialysis. Biochemical Pharmacology. 51(7). 987–992. 16 indexed citations
7.
Vore, Mary, Tim Hoffman, & Michael P. Gosland. (1996). ATP-dependent transport of beta-estradiol 17-(beta-D-glucuronide) in rat canalicular membrane vesicles. American Journal of Physiology-Gastrointestinal and Liver Physiology. 271(5). G791–G798. 20 indexed citations
8.
Gillespie, M. N., et al.. (1996). The potential of a novel polyamine transport inhibitor in cancer chemotherapy.. Journal of Pharmacology and Experimental Therapeutics. 278(1). 185–192. 23 indexed citations
9.
Huang, Liyue, et al.. (1996). MDR1 substrates/modulators protect against beta-estradiol-17beta-D-glucuronide cholestasis in rat liver.. PubMed. 56(21). 4992–7. 31 indexed citations
10.
Gosland, Michael P. & Bert L. Lum. (1995). The Anticancer Drugs, 2nd Edition. Annals of Pharmacotherapy. 29(3). 320–320. 2 indexed citations
11.
Gosland, Michael P., et al.. (1995). A phase I trial of 5-day continuous infusion cisplatin and interferon ?. Cancer Chemotherapy and Pharmacology. 37(1-2). 39–46. 2 indexed citations
12.
Lum, Bert L. & Michael P. Gosland. (1995). MDR Expression in Normal Tissues: Pharmocologic Implication for the Clinical Use of P-Glycoprotein Inhibitors. Hematology/Oncology Clinics of North America. 9(2). 319–336. 113 indexed citations
13.
Gosland, Michael P., et al.. (1995). A novel polymeric spermine conjugate inhibits polyamine transport in pulmonary artery smooth muscle cells.. Journal of Pharmacology and Experimental Therapeutics. 274(1). 181–186. 17 indexed citations
14.
Baker, James L., Michael P. Gosland, Jon D. Herrington, & Kenneth E. Record. (1994). Cytomegalovirus Colitis After 5‐Fluorouracil and Interferon‐α Therapy. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 14(2). 246–249. 9 indexed citations
15.
Baker, James L., et al.. (1994). Cytomegalovirus colitis after 5-fluorouracil and interferon-alpha therapy.. PubMed. 14(2). 246–9. 12 indexed citations
16.
Lum, Bert L., Michael P. Gosland, Sonja Kaubisch, & Branimir I. Šikić. (1993). Molecular Targets in Oncology: Implications of the Multidrug Resistance Gene. Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy. 13(2). 88–109. 84 indexed citations
17.
Fisher, George A., N A Brophy, Joanne Halsey, et al.. (1992). Phase I trial of etoposide with cyclosporine as a modulator of multidrug resistance.. Journal of Clinical Oncology. 10(10). 1624–1634. 192 indexed citations
18.
Lum, B L, Sonja Kaubisch, N A Brophy, et al.. (1992). Alteration of etoposide pharmacokinetics and pharmacodynamics by cyclosporine in a phase I trial to modulate multidrug resistance.. Journal of Clinical Oncology. 10(10). 1635–1642. 249 indexed citations
19.
Jacobs, Charlotte, Sonja Kaubisch, Joanne Halsey, et al.. (1991). The use of probenecid as a chemoprotector against cisplatin nephrotoxicity. Cancer. 67(6). 1518–1524. 41 indexed citations
20.
Gosland, Michael P., B L Lum, & Branimir I. Šikić. (1989). Reversal by cefoperazone of resistance to etoposide, doxorubicin, and vinblastine in multidrug resistant human sarcoma cells.. PubMed. 49(24 Pt 1). 6901–5. 67 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by C.M. Kuiper Breakdown of academic impact, for papers by C. H. M. Versantvoort Breakdown of academic impact, for papers by C.K. van Kalken Breakdown of academic impact, for papers by Kieran L. O’Loughlin Breakdown of academic impact, for papers by Elizabeth Hopper-Borge Breakdown of academic impact, for papers by Junko Mitsuhashi Breakdown of academic impact, for papers by Ken Shiozawa Breakdown of academic impact, for papers by Irina Shchaveleva Breakdown of academic impact, for papers by G L Scheffer Breakdown of academic impact, for papers by D D Ross
Rankless by CCL
2026